Events Calendar

Mon
Tue
Wed
Thu
Fri
Sat
Sun
M
T
W
T
F
S
S
30
2
4
5
6
8
9
10
11
12
13
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
World Congress on Medical Toxicology
2020-12-01 - 2020-12-02    
12:00 am
World Congress on Medical Toxicology Medical Toxicology Pharma 2020 provides a global platform to meet and develop interpersonal relationship with the world’s leading toxicologists, pharmacologists, [...]
01 Dec
2020-12-01 - 2020-12-02    
All Day
International Conference on Food Technology & Beverages” at Kyoto, Japan in the course of Kyoto, Japan, December, 01-02, 2020 Theme of the Food Tech 2020 [...]
Biomedical, Bio Pharma and Clinical Research
2020-12-03 - 2020-12-04    
12:00 am
Biomedical, Bio Pharma and Clinical Research Conference Series LLC LTD cordially invites you to be a part of “2nd International Conference on Biomedical, Bio Pharma [...]
NODE Health 4th Annual Digital Medicine Conference
2020-12-07 - 2020-12-12    
12:00 am
NODE.Health is delighted to announce the 4th Annual Digital Medicine Conference - Evidence Matters. Never before has the transformation of our healthcare system been more [...]
2020 Global Digital Health Forum
2020-12-07 - 2020-12-09    
12:00 am
Organized by Global Digital Health Network Digital health can be the great leveler – it can give anyone access to information about health and disease. [...]
International Conference on Cancer Treatment and Prevention
2020-12-14 - 2020-12-15    
12:00 am
Cancer Treatment Forum 2020 regards each one of the individuals to go to the "Cancer Treatment Forum 2020" amidst December 15, 2020 UK-Time Zone( GMT [...]
International Conference on Neurology and Neural Disorders
2020-12-14 - 2020-12-15    
12:00 am
International Conference on Neurology and Neural Disorders Neurology Research 2020 will join world-class professors, scientists, researchers, students, perfusionist, neurologist to discuss methodology for ailment remediation [...]
Events on 2020-12-03
Articles

Nov 16: EHR Association Backs No FDA Regulation For EHR Systems

fda regulation

The Electronic Health Record Association, which represents 40 EHR developer companies whose products are in use at a majority of hospitals and physician practices today, applauds an FDA Regulation workgroup recommendation that healthcare technology, such as EHR systems, should not be treated as medical devices and should remain unregulated.

However, the group, in a Nov. 6 letter to HHS Secretary Kathleen Sebelius, asked for clarification on a number of topics, including clinical decision support, medical device accessories, reporting of safety event and post-market surveillance and “Class 0.”

“We are not convinced that most HIT not regulated as a medical device should receive a new ‘Class 0’ device classification by the FDA. Such a classification and application for a formal regulatory approach to HIT is not warranted in our view,” stated the letter signed by the EHR Association Executive Committee members, whose chair is Michele McGlynn, senior director, strategy and operations at Siemens.

The Association recommended the following:

  • Any definition of HIT used in a new risk-based policy framework should align with existing market definitions. The focus should be on what specific types of HIT are subject to which types of regulation or oversight, if any.
  •  A patient safety risk framework and examples should be used as building blocks to develop a robust and transparent plan that that would allow application of oversight by level of risk and associated costs and benefits of oversight. Any such framework must include weights for risk elements and a model to combine results.
  • To the extent that enforcement discretion is used, it should be used in a manner that creates greater predictability as opposed to regulatory uncertainty, with enforcement discretion identified as the clear outcome of a considered policy process and one that can be expected to remain in place for some time. We believe that the approach taken related to the recent FDA guidance on mobile devices is a good example of providing useful guidance and minimizing uncertainty, while allowing the framework and the market to evolve. As a general proposition, we urge that any deliberations regarding increased oversight of HIT be conducted in ways that increase predictability and certainty for developers and providers

source